65% of Americans haven't considered GLP-1s for weight loss
Core finding
Most Americans (65%) have not considered using a GLP-1 medication such as Ozempic or Wegovy to lose weight, according to a survey Verasight fielded from December 2025 into January 2026.
Another 12% have considered it briefly, 11% have seriously weighed it, and 12% are currently taking one.
Topline distribution
65% of Americans haven't considered GLP-1s for weight loss.
Have you considered using a GLP-1 medication to lose weight (e.g., Ozempic, Wegovy, etc)?
n = 1,000 · Dec 22, 2025 – Jan 5, 2026 · MoE ±3.1%
Methodology
Full methodology →| Mode | Verasight panel recruited via random address-based sampling, random person-to-person text messaging, and dynamic online targeting |
|---|---|
| Population | United States adults |
| Field dates | Dec 22, 2025 – Jan 5, 2026 |
| Base (unweighted) | 1,000 |
| Margin of error | ±3.1% |
| Module | predictions |
| Sponsor | Verasight |
| Weight variable | weight for AI and predictions questions; weight_popculture for pop culture questions |
| Weighting targets | age, race/ethnicity, sex, income, education, region, metropolitan status |
Sources
- reports.verasight.io/r/2026-predictions
Have you considered using a GLP-1 medication to lose weight (e.g., Ozempic, Wegovy, etc)?
Cite this question
2026 Predictions Survey #2025-183, fielded December 22, 2025-January 5, 2026, N=1,000 United States adults, +/- 3.1%.